|
2025 Journal Article Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyChin, Wee Loong, Cook, Alistair M., Chee, Jonathan, Principe, Nicola, Hoang, Tracy S., Kidman, Joel, Hmon, Khaing P.W., Yeow, Yen, Jones, Matthew E., Hou, Rui, Denisenko, Elena, McDonnell, Alison M., Hon, Chung-Chau, Moody, Jonathan, Anderson, Denise, Yip, Sonia, Cummins, Michelle M., Stockler, Martin R., Kok, Peey-Sei, Brown, Chris, John, Thomas, Kao, Steven C.-H., Karikios, Deme J., O'Byrne, Kenneth J., Hughes, Brett G.M., Lake, Richard A., Forrest, Alistair R.R., Nowak, Anna K., Lassmann, Timo and Lesterhuis, W. Joost (2025). Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell Reports Medicine, 6 (1) 101882, 1-18. doi: 10.1016/j.xcrm.2024.101882 |
|
2025 Journal Article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6Hughes, Brett G.M., Guminski, Alexander, Bowyer, Samantha, Migden, Michael R., Schmults, Chrysalyne D., Khushalani, Nikhil I., Chang, Anne Lynn S., Grob, Jean-Jacques, Lewis, Karl D., Ansstas, George, Day, Fiona, Ladwa, Rahul, Stein, Brian N., Muñoz Couselo, Eva, Meier, Friedegund, Hauschild, Axel, Schadendorf, Dirk, Basset-Seguin, Nicole, Modi, Badri, Dalac-Rat, Sophie, Dunn, Lara A., Flatz, Lukas, Mortier, Laurent, Guégan, Sarah, Heinzerling, Lucie M., Mehnert, Janice M., Trabelsi, Sabiha, Soria-Rivas, Ainara, Stratigos, Alexander J. ... Rischin, Danny (2025). A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6. Journal of the American Academy of Dermatology, 92 (1), 68-77. doi: 10.1016/j.jaad.2024.06.108 |
|
2025 Journal Article Development of a circulating tumour cell culture model from head and neck squamous cell carcinomaHuang, Xiaomin, Zhang, Xi, Weeramange, Chameera Ekanayake, Leo, Paul, Hughes, Brett G. M., Dolcetti, Riccardo, Zeng, Bijun, Mazzieri, Roberta, Hartel, Gunter, Ladwa, Rahul, Taheri, Touraj, Breik, Omar, Kenny, Lizbeth, Vasani, Sarju and Punyadeera, Chamindie (2025). Development of a circulating tumour cell culture model from head and neck squamous cell carcinoma. VIEW, 6 (6) 20250085. doi: 10.1002/VIW.20250085 |
|
2025 Journal Article Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancerCorvino, Dillon, Batstone, Martin, Hughes, Brett G. M., Kempchen, Tim, Ng, Susanna S, Salim, Nazhifah, Schneppenheim, Franziska, Rommel, Denise, Kumar, Ananthi, Pearson, Sally, Madore, Jason, Koufariotis, Lambross T., Steinheuer, Lisa Maria, Pathirana, Dilan, Thurley, Kevin, Hölzel, Michael, Borcherding, Nicholas, Braun, Matthias and Bald, Tobias (2025). Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancer. European Journal of Immunology, 55 (1) e202451371, 1-13. doi: 10.1002/eji.202451371 |
|
2025 Journal Article Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaMachiels, J. P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D., Alves, G. V., Lima, I. P.F., Hughes, B. G.M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Delord, J. P., Mesia, R., Taberna, M., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Black, C. M., Norquist, J. M., Wang, A., Gumuscu, B., Bidadi, B. and Siu, L. L. (2025). Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. Frontiers in Oncology, 15 1645509, 1645509. doi: 10.3389/fonc.2025.1645509 |
|
2025 Journal Article Tumour-informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatmentHuang, Xiaomin, Leo, Paul, Clout, Mhairi, Fink, Lynn, Ellis, Jonathan, Hughes, Brett G. M., Kenny, Lizbeth, Vasani, Sarju and Punyadeera, Chamindie (2025). Tumour-informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatment. VIEW 20250112. doi: 10.1002/VIW.20250112 |
|
2024 Journal Article Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patientsZhang, Xi, Weeramange, Chameera Ekanayake, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz, Breik, Omar and Punyadeera, Chamindie (2024). Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients. Cellular and Molecular Life Sciences, 81 (1) 233, 1-14. doi: 10.1007/s00018-024-05269-1 |
|
2024 Journal Article Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort studyChow, Kar Ven Cavan, Turner, Cassie, Hughes, Brett, Lwin, Zarnie and Chan, Bryan (2024). Real‐world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. Asia-Pacific Journal of Clinical Oncology, 20 (6), 723-730. doi: 10.1111/ajco.14098 |
|
2024 Journal Article Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapyBrown, Teresa E., Byrnes, Angela, Chan, Aaron C., Dwyer, Kathleen, Edwards, Anna, Blake, Claire L., Banks, Merrilyn D., Hughes, Brett G. M., Lin, Charles Y., Kenny, Lizbeth M., Spurgin, Ann-Louise and Bauer, Judith D. (2024). Revalidation of proactive gastrostomy tube placement guidelines for head and neck cancer patients receiving helical intensity-modulated radiotherapy. Current Oncology, 31 (11), 6938-6955. doi: 10.3390/curroncol31110512 |
|
2024 Journal Article Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 TrialAnnageldiyev, Charyguly, Gaudreau, Pierre-Olivier, Leitzel, Kim, Ali, Suhail M., Ding, Keyue, Leighl, Natasha B., Vera Badillo, Francisco Emilio, Bradbury, Penelope Ann, Goss, Glenwood D., Shepherd, Lois E., Costa, Luis, Suva, Larry J., Hughes, Brett G.M., Stockler, Martin R., Drabick, Joseph J., Ma, Patrick C., Joshi, Monika, Moku, Prashanth, Polimera, Hyma V., Louis, Patricia, Ramachandrula, Priya and Lipton, Allan (2024). Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial. JCO Oncology Advances (1). doi: 10.1200/oa.24.00017 |
|
2024 Journal Article Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy responseSadeghirad, Habib, Monkman, James, Tan, Chin Wee, Liu, Ning, Yunis, Joseph, Donovan, Meg L., Moradi, Afshin, Jhaveri, Niyati, Perry, Chris, Adams, Mark N., O’Byrne, Ken, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. Journal of Translational Medicine, 22 (1) 677, 677. doi: 10.1186/s12967-024-05409-y |
|
2024 Journal Article A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinomaLadwa, Rahul, Chandra, Janin, Woo, Wai-Ping, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Xu, Yan, Panizza, Benedict, Frazer, Ian and Porceddu, Sandro V. (2024). A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Frontiers in Oncology, 14 1419258, 1-8. doi: 10.3389/fonc.2024.1419258 |
|
2024 Journal Article Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyCho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Wilson H., Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F. and Hughes, Brett G. M. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer, 23 (Suppl 1) 1254, 1-12. doi: 10.1186/s12885-023-11316-0 |
|
2024 Journal Article Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trialSolomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven and Bauer, Todd M. (2024). Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trial. JTO Clinical and Research Reports, 5 (7) 100685. doi: 10.1016/j.jtocrr.2024.100685 |
|
2024 Conference Publication A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-SquamateLadwa, Rahul, Lee, Jenny H.J., Porceddu, Sandro V., McGrath, Margaret Louise, Cooper, Caroline, Liu, Howard, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle K., Clark, Jonathan, Le, Dieu, Pauley, Marketa, Gonzalez-Cruz, Jazmina, Frazer, Ian, Hughes, Brett Gordon Maxwell and Panizza, Benedict J. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.9514 |
|
2024 Journal Article Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancerFelip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G. M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I. and Cobo, Manuel (2024). Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer. Lung Cancer, 192 107820, 107820. doi: 10.1016/j.lungcan.2024.107820 |
|
2024 Journal Article Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialMachiels, Jean-Pascal, Tao, Yungan, Licitra, Lisa, Burtness, Barbara, Tahara, Makoto, Rischin, Danny, Alves, Gustavo, Lima, Iane Pinto Figueiredo, Hughes, Brett G M, Pointreau, Yoann, Aksoy, Sercan, Laban, Simon, Greil, Richard, Burian, Martin, Hetnał, Marcin, Delord, Jean-Pierre, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, Bidadi, Behzad, Siu, Lillian L, Hughes, Brett GM, Gao, Bo ... Obara, Grzegorz S (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 25 (5), 572-587. doi: 10.1016/S1470-2045(24)00100-1 |
|
2024 Journal Article Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in QueenslandPorceddu, Sandro, Negrello, Theresa, Rawson, Neal, Dunn, Nathan, Batstone, Martin, Collins, Michael, Dowthwaite, Sam, Hughes, Brett G. M., Kenny, Liz, Ladwa, Rahul, Panizza, Ben and Cossio, Danica (2024). Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. Journal of Medical Imaging and Radiation Oncology, 68 (4), 472-480. doi: 10.1111/1754-9485.13643 |
|
2024 Conference Publication Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy responseSadeghirad, Habib, Tan, Chin Wee, Liu, Ning, Monkman, James, Cooper, Caroline, O’Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2024). Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-1154 |
|
2024 Conference Publication Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactionsSadeghirad, Habib, Naei, Vahid Yaghoubi, Monkman, James, Basu, Subham, Wicher, Agata, Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactions. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-5188 |
